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Abstract Hepatic ischemia/reperfusion (I/R) injury is a
common clinical challenge. Despite accumulating evidence
regarding its mechanisms and potential therapeutic
approaches, hepatic I/R is still a leading cause of organ
dysfunction, morbidity, and resource utilization, especially
in those patients with underlying parenchymal abnormali-
ties. In the oncological setting, there are growing concerns
regarding the deleterious impact of I/R injury on the risk of
post-surgical tumor recurrence. This review aims at giving
the last updates regarding the role of hepatic I/R and liver
parenchymal quality injury in the setting of oncological
liver surgery, using a ‘‘bench-to-bedside’’ approach. Rele-
vant medical literature was identified by searching PubMed
and hand scanning of the reference lists of articles con-
sidered for inclusion. Numerous preclinical models have
depicted the impact of I/R injury and hepatic parenchymal
quality (steatosis, age) on increased cancer growth in the
injured liver. Putative pathophysiological mechanisms
linking I/R injury and liver cancer recurrence include an
increased implantation of circulating cancer cells in the
ischemic liver and the upregulation of proliferation and
angiogenic factors following the ischemic insult. Although
limited, there is growing clinical evidence that I/R injury
and liver quality are associated with the risk of post-sur-
gical cancer recurrence. In conclusion, on top of its harmful
early impact on organ function, I/R injury is linked to
increased tumor growth. Therapeutic strategies tackling I/R
injury could not only improve post-surgical organ function,
but also allow a reduction in the risk of cancer recurrence.
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Introduction
Ischemia–reperfusion (I/R) injury is a process whereby
parenchymal damage caused by blood flow deprivation is
accentuated upon organ reperfusion. I/R injury is a com-
mon clinical challenge, as it arises in various clinical sce-
narios such as cerebrovascular disease [1], circulatory
shock [2], cardiovascular [3] and liver surgery [4], and
transplantation medicine [5, 6]. I/R injury, through the
liberation of radical oxygen species and the activation of
inflammatory pathways, induces cellular injury and mi-
crocirculatory damage, which translate to organ dysfunc-
tion, morbidity, and increased health care costs [7, 8]. In
L. A. Orci (&)  S. Lacotte  G. Oldani  P. Morel 
G. Mentha  C. Toso (&)
Division of Abdominal and Transplantation Surgery, Department
of Surgery, Geneva University Hospitals and Faculty of
Medicine, University of Geneva, 4 rue Gabrielle-Perret-Gentil,
1211 Geneva, Switzerland
e-mail: lorenzo.orci@hcuge.ch
C. Toso
e-mail: christian.toso@hcuge.ch
S. Lacotte
e-mail: stephanie.lacotte@unige.ch
G. Oldani
e-mail: Graziano.oldani@hcuge.ch
P. Morel
e-mail: Philippe.morel@hcuge.ch
G. Mentha
e-mail: Gilles.mentha@hcuge.ch
L. A. Orci  G. Oldani  P. Morel  G. Mentha  C. Toso
Hepato-Pancreato-Biliary Centre, Geneva University Hospitals
and Faculty of Medicine, University of Geneva, 4 rue
Gabrielle-Perret-Gentil, 1211 Geneva, Switzerland
123
Dig Dis Sci (2014) 59:2058–2068
DOI 10.1007/s10620-014-3182-7
the liver, I/R injury is at the source of poor outcomes after
surgical procedures such as hepatectomy and liver trans-
plantation [7].
Lowering intraoperative blood loss during hepatectomy
is a crucial factor determining the success of liver resec-
tion, as surgical bleeding and transfusion are associated
with poor outcomes in both the short- and long term [9–
11]. Thus, liver surgeons have the option to apply vascular
inflow control procedures and sometimes total vascular
exclusion to reduce intraoperative bleeding. The major
drawback of such strategies is that they can induce I/R
injury to the residual liver parenchyma [4, 12]. In liver
transplantation, tissue damage at reperfusion is mostly
correlated with warm and cold ischemia times and leads in
turn to poor graft function [13] and biliary complications
[14, 15].
In addition to the direct I/R-mediated harmful effect on
the liver parenchyma, underlying organ physiology and the
presence of pre-established tissue lesions (e.g., steatosis)
interact with I/R injury [16]. Hepatic steatosis increases
susceptibility of the liver to I/R injury through microcir-
culatory dysfunction caused by sinusoid compression by
lipid droplets [17–19] and reduced cellular energy stock
and cell membrane disruption via I/R-mediated lipid per-
oxidation [20]. Moreover, aged livers also appear to be less
tolerant to I/R injury [21]. This is particularly relevant to
the transplantation setting, where the use of marginal
donors, such as (macro-) steatotic graft or livers from older
donors, has been shown to be associated with poorer out-
comes after liver transplantation [22, 23].
Besides jeopardizing patients’ outcome in the early post-
operative period, there are growing concerns surrounding
the role of hepatic I/R injury and surgical trauma in the
oncological setting. Surgical manipulation of the liver
induces the release of cancer cells in the blood stream,
which could in turn engraft into the remnant liver or into the
newly transplanted liver graft and constitute the source of
tumor recurrence [24, 25]. I/R injury induces the expression
of cytokines, growth factors, and adhesion molecules that
have been repeatedly reported to foster tumor growth [26–
28]. The aim of this review was to give the last updates
regarding the role of hepatic I/R injury with regard to
oncological outcomes, focusing on experimental models
used to assess this issue, clinical evidence, and potential
therapeutic strategies aimed at reducing the risk of I/R-
mediated post-surgical tumor recurrence. Both the settings
of liver resection and transplantation will be explored.
Methods
The design of the current manuscript consists of a narrative
(non-systematic) review. Of note, systematic reviews of
experimental studies are feasible [29] and may help answer
a specific research question. Despite such a design would
have been a possibility, the multiple settings and research
questions (liver resection: pedicle vs. no pedicle clamping,
hemi-vascular occlusion, therapeutic strategies; liver
transplantation: donation after cardiac death, small-for-
size) that were aimed to be addressed here fostered us to
undertake a narrative review. A literature search was per-
formed in Medline, using the following keywords: ische-
mia–reperfusion, steatosis, small-for-size, liver cancer,
hepatocellular carcinoma, colorectal metastases, colon
adenocarcinoma, and tumor growth. Only studies written
English and published in peer-reviewed journals were
considered for inclusion. Studies were categorized
according to their research design (experimental, clinical
retrospective, and clinical prospective). Study eligibility
for inclusion was based on their ability to provide com-
posite insight into the link between liver parenchyma and
cancer behavior and to guide the reader to relevant primary
and secondary sources for further reading.
Discussion
Preclinical Evidence
Hepatic Ischemia–Reperfusion Injury Enhances Hepatic
Tumor Growth
There are reports dating back to the 1960s where ischemic
tissue was observed to offer a favorable environment for
the implantation and growth of blood-borne metastases [30,
31]. In the liver, to evaluate the link between hepatic I/R
injury and cancer behavior, research groups have used
several hepatic I/R injury models complemented with the
inoculation of different tumor cell lineages (Table 1). In a
rat colon adenocarcinoma metastasis model, Kurata et al.
[32] showed that, compared to sham-operated animals,
30-min partial (median and left lobes) ischemia to the liver
induced a 14-fold increase in the number of metastatic
nodules (p \ 0.01). Using a mouse colon adenocarcinoma
model, Gorden et al. reported similar findings, with an
increase in both the number of nodules and tumor volume
in animals undergoing a 30-min course of 70 % ischemia
(via clamping of the median and left lobes) [33]. In another
experiment using a hepatocellular carcinoma (HCC) cell
line, Man et al. [34] observed markedly higher tumor
growth and invasiveness in those animals subjected to a
60-min period of ischemia followed by 60 min of reper-
fusion as compared to sham-operated animals. Several
other preclinical reports [35–38] explored the impact of
hepatic I/R injury on tumor growth and metastatic poten-
tial, as illustrated in Table 1.
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Table 1 Ischemia–reperfusion injury fosters liver metastases, experimental models
Doi [40] Rat 30 versus 60 min 70 % ischemia Colon
adenocarcinoma
(RCN-H4)
: E-selectin in liver tissue of ischemic groups
compared to control
Doi [35] Rat 60 min 70 % ischemia Colon
adenocarcinoma
(RCN-H4)
Administration of neutrophil elastase inhibitor
(ONO-5046) after I/R reduced the number of
hepatic metastases
Yoshida
[37]
Rat Continuous: 60 min 70 % ischemia
Intermittent: 15 min periods of 70 %
ischemia (49), with 15 min of
reperfusion between ischemia
Colon
adenocarcinoma
(RCN-H4)
; E-selectin in liver tissue of the intermittent
ischemia group compared to continuous ischemia
Van der
Bilt [62]
Mouse Continuous: 45 min 40 % ischemia
Intermittent: 15 min periods o 40 %
ischemia (93), with 5 min of reperfusion
between ischemia
Ischemic pre-conditioning: 10 min 40 %
ischemia, followed by 15 min of
reperfusion, before 45-min 40 %
ischemia
Colon
adenocarcinoma
(C26)
Accelerated tumor growth localized around necrotic
tissue areas. Ischemic lobes show lowered levels
of glutathione compared to non-ischemic lobes
Kurata [32] Rat 30 min 70 % ischemia followed by
resection of non-ischemic lobes
Colon
adenocarcinoma
(RCN-H4)
Antithrombin inhibited the increase in the number
of metastatic nodules in animals subjected to I/R
injury, by blunting the TNF-a-induced expression
of E-selectin, through an increase in endothelial
PGI2 production
Man [34] Rat 60 min 60 % ischemia
60 min 60 % ischemia plus major
hepatectomy
Hepatoma (MCA-
RH7777)
: Proliferation (PCNA staining) of tumor cells and
VEGF in the ischemic group, : invasiveness
genetic profile (expression of ROCK and Cdc-42)
in animals receiving both I/R and hepatectomy
Van der
Bilt [82]
Mouse 45 min 40 % ischemia Colon
adenocarcinoma
(C26)
I/R injury-mediated tumor growth occurs
preferentially in areas of tissue hypoxia, and
elevated HIF-1a expression
HIF-1a was detected in nuclei of tumor cells at the
tumor-necrosis margin in the ischemic group
Attenuation of microcirculatory damage, hypoxia
and hepatocellular damage by atrasentan/L-
arginine allows a reduced tumor outgrowth
Nicoud
[33]
Mouse 30 min 70 % ischemia Colon
adenocarcinoma
(MC38)
: MMP9 mRNA and protein expression in liver
tissue of ischemic group
Doxycycline inhibits I/R-induced MMP9, and
decreases hepatic metastases
Genetic deletion of MMP9 prevents hepatic
metastases
Van der
Bilt [39]
Mouse Ischemia time: 20 min versus 30 min
versus 45 min 40 % ischemia
Steatosis: 6-week high-fat diet versus
normal diet
Age: Adult mice (12–13 months) versus
10–12 weeks
Gender: male versus female
Colon
adenocarcinoma
(C26)
Steatosis and male gender lead to heightened I/R-
mediated tumor outgrowth
Tamagawa
[36]
Rat 60 min 70 % ischemia Colon
adenocarcinoma
(RCN-H4)
: Plasma and liver tissue VEGF in the ischemic
group compared to control
Yoshimoto
[38]
Nude
mouse
20-min total ischemia Human pancreatic
cancer (Capan-
1)
: E-selectin in liver tissue of the ischemic group
compared to control
I/R ischemia/reperfusion, VEGF vascular endothelial growth factor, MMP-9 matrix metalloproteinase-9, HIF-1a hypoxia-inducible factor 1a,
PCNA proliferating cell nuclear antigen, PGI2 prostaglandin I2, ROCK Rho-associated protein kinase, Cdc-42 cell division control protein 42
homolog
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Looking at the impact of duration of ischemia on I/R
injury-mediated metastasis development, van der Bilt et al.
reported significant differences in terms of hepatic metas-
tases growth according to the duration of warm ischemia.
Mice subjected to 20 min of ischemia had a similar tumor
burden compared to non-ischemic liver tissue (sham-
operated animals or non-clamped liver lobes). In contrast,
after 30 and 45 min of ischemia, mice had a significantly
increased tumor burden compared to non-ischemic controls
[39]. In the same way, Doi et al. observed that rats
undergoing 60-min segmental (70 %) hepatic ischemia
developed significantly more nodules than rats subjected to
30-min pedicle clamping. Contrasting with the findings by
the Utrecht group that observed a five- to sixfold acceler-
ated tumor outgrowth in the ischemic liver as compared to
non-occluded lobes, Doi et al. reported that I/R injury leads
to increased tumor growth in all liver lobes (even the non-
clamped lobes), suggesting a dissemination of the effect of
I/R injury to liver tissue not directly enduring parenchymal
damage [40]. Although apparently self-contradictory, these
differences could be linked to several divergences in the
models used. First, the experiments were undertaken in two
different animal models (rat [40] vs. mouse [39]) remind-
ing that pathophysiological pathways may differ according
to the species under investigation. Second, the sequence of
procedures applied in these two studies were not strictly
comparable: while Doi et al. [40] inoculated cancer cells in
the spleen after 60 min of reperfusion, van der Bilt et al.
[39] allowed pre-inoculated cells to circulate for 5 days
before the induction of I/R injury. Based on these obser-
vations, one could speculate that variability in terms of
cancer cell concentration in the portal system (markedly
more increased after an intrasplenic bolus administered
following 60 min of reperfusion [40] than after a 5-day-
long homogeneous dilution in the blood stream [39]), could
affect their implantation in the liver. Altogether, regardless
of heterogeneity in the experimental models used, there is
accumulating experimental evidence uniformly reporting
I/R injury to be associated with increased hepatic meta-
static potential and increased tumor growth (Table 1).
The Impact of Liver Resection and Small-for-Size Livers
on Tumor Behavior
The association between partial liver resection and
increased metastases growth was originally described in
the semantic experiments by Fisher and colleagues in the
1950s, where rats undergoing partial hepatectomy (70 %)
were threefold more likely to develop liver metastases after
intraportal cancer cell injection as compared to controls
[41]. Since then, numerous research groups have confirmed
that hepatic resection induced by itself increased tumor
recurrence [42–47]. The two pivotal components of post-
resection tumor recurrence (the engraftment of circulating
cancer cell and the increased tumor growth of microme-
tastases) were thoroughly reviewed by de Jong et al. [48].
More recently, insufficient post-hepatectomy remnant liver
parenchyma, referred to as small-for-size syndrome, has
been evaluated as a determinant of tumor recurrence [34].
On top of being a potential cause of post-operative liver
failure and a common clinical challenge in liver surgery
[49, 50], small-for-size syndrome causes acute phase
mechanical injury, which induces lesions similar to those
observed in hepatic I/R injury [51, 52]. Therefore, small-
for-size liver models have been used to assess the rela-
tionship between parenchymal injury and circulating tumor
cell engraftment. Man and co-workers evaluated the inva-
siveness and cell migration pathways of intraportally
injected HCC cells in rats undergoing major hepatectomy
(left and caudate lobes, 50–60 % of total liver volume)
with or without 60-min ischemia and 60-min reperfusion to
the right and median lobes (40–50 % of total liver volume)
[34]. This experiment showed not only that small-for-size
injury increases tumor growth by itself, but also that I/R
injury of the liver remnant leads to increased tumor
aggressiveness and metastatic potential (both intra- and
extra-hepatic) [34]. Going one step further, rat tumor tissue
harvested from original livers was re-implanted in the
livers of nude mice undergoing different surgical stress
conditions (major hepatectomy alone, I/R injury alone, I/R
injury and major hepatectomy, and sham). This unique
experimental design allowed demonstrating that the surgi-
cal stress resulting from hepatic I/R injury and/or major
hepatectomy not only makes the hepatic microenvironment
favorable for tumor cell growth, migration, and invasion
through stimulation of acute phase inflammatory response
and disturbance of microcirculatory barrier function, but it
also makes the tumor cells more aggressive by directly
activating cell migration and invasion pathways [34].
In addition to its impact on the remnant liver after
hepatectomy, small-for-size syndrome is a frequent sce-
nario affecting graft function in the transplantation setting.
Small-for-size injury has been pointed out as a potential
mediator of post-liver transplantation tumor recurrence.
Thus, to export the evidence gathered from the liver
resection setting, Man et al. [53] analyzed, in a rat liver
transplantation model, the effect of small-for-size injury
(achieved by removal of the left and caudate liver lobes) on
post-liver transplantation tumor growth. Animals receiving
small-for-size livers experienced early endothelial injury,
and sinusoidal damage, followed by parenchymal necrosis
and sinusoidal microthrombi, characterizing the role of
small-for-graft size injury. Hepatic replacement area by
circulating HCC cells was significantly increased in the
small-for-size group compared to the whole liver group. To
assess the stimulation of I/R injury on tumor invasiveness,
Dig Dis Sci (2014) 59:2058–2068 2061
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Man et al. [53] used again an orthotopic xenogeneic tumor
model, harvesting tumor tissue grown in rat liver grafts and
implanting it in the liver of nude mice. Six weeks post-
implantation, tumors arising from the small-for-size graft
group reached higher tumor volumes and developed more
distant metastases. These findings show that on top of
damaging graft function, acute phase I/R injury promotes
late phase tumor growth and invasiveness.
Although the use of marginal liver grafts, including
from donation after cardiac death (DCD), has been shown
to be a reasonable option in the face of organ shortage,
marginal grafts are more susceptible to I/R injury [54]. The
current authors have shown that I/R lesions associated with
rat liver transplantation from DCD donors lead to increased
post-transplant HCC recurrence and growth [55]. More-
over, looking at potential therapeutic strategies, it could be
demonstrated that the use of normothermic reperfusion
modalities allows a reduction in I/R lesions, and in turn of
post-transplant HCC recurrence and growth, restoring HCC
tumor volume to the level of non-ischemic, control animals
[55].
Clinical Implications
Liver Resection
The impact of vascular inflow control procedures on the
risk of cancer recurrence after liver surgery has been
evaluated in a limited number of clinical studies. Nijkamp
et al. have shown that severe ischemia, defined as a con-
tinuous portal triad clamping for more than 20-min or more
than three cycles of 15-min intermittent clamping, was
associated with increased cancer relapse rates after liver
resection for colorectal metastases [adjusted hazard ratio
(HR) = 1.37 (95 % CI 1.02–1.85), p = 0.038] [56]. In
contrast, Giuliante et al. [57] observed no difference in
terms of hepatic recurrence rate according to the use, type,
and duration of hepatic pedicle clamping [57]. In another
recent retrospective series including 386 patients under-
going hepatectomy for HCC with (n = 224) or without
(n = 162) pedicle clamping, Xia et al. [58] reported no
difference between study groups in terms of 1-, 3-, and
5-year disease-free or overall survival. The overall recur-
rence rate was 67 % (66.1 and 67.3 % for patients with or
without pedicle clamping, p = 0.828), with a median time
to recurrence of 26 months. Intra- versus extra-hepatic
recurrence was also comparable between study groups
[58]. A long-term analysis of a randomized clinical trial
assessed the role of Pringle maneuver on post-resection
colorectal liver metastases recurrence and did not detect
differences between those undergoing vascular inflow
control or not [overall survival at 1, 3, and 5 years, portal
clamping group: 100, 86.1, and 49.4 % vs. no clamping
group: 92.6, 65.8, and 48.2 % (p = 0.704)] [59]. Disease-
free survival was also similar between the two groups: 1-,
3- and 5-year survival rates were 85.7, 51.4, and 34.3 % in
the HPC group versus 84, 51.5, and 37.9 %, respectively
(p = 0.943). Although these data arise from a prospective
randomized study, between-group follow-up differences
[median follow-up was 67.1 ± 20 months in the Pringle
maneuver group versus 77.5 ± 16.6 months in the control
group (p = 0.07)] and the small sample size represent
shortcomings to this secondary analysis [59]. A recent
meta-analysis did not detect any pooled difference in terms
of intra-hepatic recurrence, disease-free survival, or overall
survival between patients undergoing liver resection for
colorectal metastases with or without pedicle clamping
[60]. A prospective randomized study evaluating the effect
of the Pringle maneuver on the risk of post-hepatectomy
recurrence is currently ongoing [61]. This trial should shed
the light on an unresolved issue and will help determining
whether findings of experimental studies translate to the
clinical setting.
In contrast to preclinical models that showed intermit-
tent portal clamping as an efficacious means of reducing
I/R injury-mediated tumor growth in the rodent [37, 62],
the evidence supporting the benefit of intermittent pedicle
clamping on tumor behavior remains very limited in the
clinical setting. In a large retrospective analysis of 563
patients undergoing liver resection for colorectal metasta-
ses, Wong et al. [63] did not find any significant difference
in terms of disease-free survival between those receiving
intermittent pedicle clamping or not. Of note, there was a
large variability in the duration of vascular occlusion
(2–104 min, median 22 min), which could have led to a
dilution effect between study groups, limiting the gener-
alizability of these findings [63].
In a retrospective analysis comparing selective and total
portal vein occlusion in 86 patients undergoing curative
hepatectomy for HCC found, Makino et al. [64] reported a
significantly longer recurrence-free survival for patients
subjected to selective portal vein occlusion (1,520 vs.
561 days, p = 0.017) in univariate analysis. After adjust-
ing for vascular invasion and number of HCC nodules, the
difference was of borderline significance [HR = 1.82
(95 % CI 0.996–3.32), p = 0.052] [64].
Because 75 % of liver blood flow that carries only
20–30 % of oxygen runs into the portal vein, it could be
argued that maintaining arterial blood flow while clamping
the portal vein only may reduce intraoperative blood loss
while minimizing I/R injury. Based on these observations,
Yang and co-workers performed a nested case–control
study evaluating the impact of portal vein occlusion with
maintenance of arterial flow (vs. complete portal triad
occlusion) on the risk of post-hepatectomy HCC recurrence
[65]. In this cohort of 169 patients, compared to those in
2062 Dig Dis Sci (2014) 59:2058–2068
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whom arterial blood flow was left untouched (n = 51),
patients undergoing combined arterial and portal blood
flow occlusion (n = 118) experienced a significantly lower
disease-free survival both in univariate analysis
(p = 0.0013), and after allowing for confounding factors
such as tumor size and grade, blood levels of alpha-feto-
protein and presence of microvascular invasion
[HR = 0.68 (95 % CI 0.54–0.86), p = 0.0015)]. In addi-
tion, arterial blood flow maintenance was accompanied by
lessened hepatocellular injury and liver function at post-
operative day one, three, and seven [65]. Of note, tumor
localization was not adjusted for, although it may affect
blood loss and the risk of post-resection recurrence. In
other words, it could be argued that surgeons tend to apply
vascular control procedures in face of more difficult cases,
which, besides being at increased risk of surgical bleeding,
probably also carry an increased risk of cancer recurrence.
Although more robust data are needed, altogether, these
findings suggest that surgical innovation may allow a
blunting in pedicle clamping-induced I/R lesions and help
achieving better oncological outcomes.
Liver Transplantation
I/R lesions, including organ injury caused by small-for-size
livers, have been repeatedly observed to be associated with
poor oncological outcomes in liver transplantation, and a
recent meta-analysis identified 16 studies comparing liv-
ing-donor liver transplantation (LDLT, a surrogate for
lower graft size) with deceased-donor liver transplantation
(DDLT) [66]. Statistical pooling of disease-free survival
revealed an aggregate HR of 1.59 (95 % CI 1.02–2.49;
p = 0.041), showing that LDLT was significantly associ-
ated with higher post-transplant HCC recurrence rates. In
contrast, pooled overall survival was not different between
LDLT and DDLT [HR = 0.97 (95 % CI 0.73–1.27;
p = 0.808)] [66]. Noteworthy is that there is a lack of
evidence as to whether common markers of I/R injury (e.g.,
cold and warm ischemia time, presence of graft steatosis,
donor age) are correlated with the risk of post-transplant
tumor recurrence. Recently, Mathur et al. [67] have shown
that increasing BMI was associated with a significantly
higher and earlier HCC recurrence rate. Looking at the
extreme scenario of marginal grafts such as DCD, Jay et al.
[68] and Croome et al. [69] pointed out that the use of DCD
donors was associated with a synergistically increased
death rate after transplantation in HCC-bearing patients as
opposed to patients without HCC. However, HCC patients
undergoing liver transplantation may die of other reasons
than tumor recurrence. In addition, these studies did not
determine actual HCC recurrence, providing only indirect
evidence of an association between donor characteristics
and poor oncological. Hence, the interpretation of donation
after cardiac death as a risk factor for post-transplant HCC
recurrence deserves further validation in the clinical
setting.
No clinical liver transplantation studies evaluating the
effectiveness of strategies blunting I/R injury as a means of
achieving improved oncological outcomes could be
identified.
Mechanisms
Underlying Parenchymal Abnormalities
The hepatic tissue does not systematically react to the
ischemic insult in the same way. Owing to the diverse
clinical situations underlying liver cirrhosis and HCC
(hepatitis B, C, alcohol, steatohepatitis) and to the complex
therapeutic strategies (chemotherapy, radiofrequency
ablation, transarterial chemoembolization) potentially
applied to patients before liver surgery, parenchymal
abnormalities appear to be involved in the post-surgical
course of patients undergoing either hepatectomy or liver
transplantation [22, 70, 71]. Fatty livers show alterations in
mitochondrial metabolism as well as increased production
of insulin-like growth factor 1, which promotes cell growth
and proliferation, and inhibits apoptosis [17, 72–74]. These
pathological changes could in turn stimulate carcinogene-
sis, making steatosis a favorable microenvironment for
tumor growth. In this mind, the Utrecht group demon-
strated that aging (12–13 months) and steatosis, as induced
by feeding mice with a high-fat diet, intensified the I/R-
induced outgrowth of colorectal adenocarcinoma microm-
etastases as compared to lean animals exposed to I/R injury
[39]. Another group went on investigating the relationship
between steatosis and hepatic tumor growth and observed
spontaneous hepatic dysplastic tumor occurrence as early
as 9 months after the introduction of a high-fat diet [75].
The number and size of tumor nodules increased over time,
and at 20 months after high-fat diet introduction, all ani-
mals developed tumor nodules. In contrast, no tumor was
detected (neither after gross or histological assessment) in
mice maintained on regular diet at the same time points.
The same group confirmed the role of a steatotic micro-
environment at favouring hepatic metastases implantation
upon observation of a significantly greater hepatic tumor
load in those animals allocated to high-fat diet as compared
to control, 21 days after tumor cell injection in the portal
system [75]. From a clinical standpoint, Hamady et al.
reported the results of a large cohort (n = 2,715) of
patients undergoing hepatectomy for colorectal liver
metastases, comparing livers with or without steatosis
(defined as a diffuse accumulation of fat droplets affecting
more than 5 % of hepatocytes) with regard to hepatic
disease-free survival [76]. After adjusting for relevant
Dig Dis Sci (2014) 59:2058–2068 2063
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confounders, the Cox proportional model showed a sig-
nificantly higher recurrence rate at 1, 3, and 5 years post-
surgery in the steatosis versus non-steatosis group (79.6,
59.2, and 52.9 % vs. 85.3, 67.1, and 61.9 %, respectively,
p \ 0.001). These results were confirmed in a matched
propensity score analysis. Although providing novel
insights into the debate of the oncological impact of fatty
liver disease, this recent study lacks a formal histological
assessment of the precise nature of fatty infiltration, which
can diverge considerably (e.g., macro- vs. microvesicular
steatosis) and differently affect post-surgical outcomes
[22].
Microcirculatory Lesions, Tissue Hypoxia,
and Angiogenesis
Microcirculatory dysfunction has been repeatedly reported
to constitute a source of hypoxia and tissue disruption in
the setting of I/R injury (Fig. 1) [77, 78]. Sustained
hypoxia to the liver promotes hypoxia-inducible factor
(HIF-)1a, which acts as a cell survival factor, and is a
promoter of tumor cell proliferation, angiogenesis, and cell
migration [79–81]. Van der Bilt et al. [39, 62, 82] dem-
onstrated on several occasions that, after I/R injury,
accelerated tumor growth predominantly surrounded
necrotic parenchyma and that I/R-mediated tumor growth
was linked to increased parenchymal HIF-1a expression
[82]. Moreover, prevention of ischemia-induced microcir-
culation disturbance with L-arginine (an enhancer of
endothelial NO synthesis) reduced the outgrowth of mi-
crometastases by minimizing tissue hypoxia and avoiding
HIF-1a stabilization [82]. Nijkamp et al. [56, 83] have
shown that I/R-mediated tumor outgrowth was also por-
tended by Fas–Fas ligand interactions, which appear to be
pivotal in the process of necrotic tissue formation.
Several reports have shown that the ischemic liver
upregulates vascular endothelial growth factor (VEGF)
expression, a well-known angiogenic factor. In the context
of liver surgery for cancer, surgical stress and I/R injury
appear to stimulate VEGF expression, which could foster
Fig. 1 Explored mechanisms suggesting a role between liver ische-
mia/reperfusion injury and cancer cell migration (bottom) and growth
(top). VEGF vascular endothelial growth factor, HIF hypoxia-
inducible factor, IL interleukin, MMP matrix metalloproteinase,
ICAM intercellular adhesion molecule, CXCL [chemokine (C-X-C
motif) ligand]
2064 Dig Dis Sci (2014) 59:2058–2068
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tumor growth through two main mechanisms. First, there is
overwhelming evidence that VEGF assumes a pivotal role
in tumor angiogenesis, and in the liver, I/R-mediated
VEGF upregulation leads to improved tumor vasculariza-
tion. Second, VEGF receptor is overexpressed on several
types of cancer cells, including colorectal cancer [36, 84,
85] and hepatocellular carcinoma cells [86], suggesting an
autocrine effect of VEGF on tumor cells expressing VEGF
receptors. Similarly, novel functions of VEGF have been
reported in various oncological settings, including the
promotion of cancer cell survival [87–89] and migration
[90].
Cell Adhesion, Migration, and Extracellular Matrix
Remodeling
Leukocyte adhesion molecules, which are expressed upon
the activation of inflammatory pathways, have been
repeatedly correlated with progression of several types of
carcinoma [91–93]. In a rat adenocarcinoma metastasis
model, Kurata et al. [32] showed the expression of
E-selectin to be significantly increased after I/R injury,
peaking at 120 min after reperfusion. E-selectin expression
correlated with ischemia duration and its expression in
ischemic tissue was accompanied by a higher number of
metastatic nodules. Intriguingly, the administration of
antithrombin reversed this IR/mediated increased tumor
burden by inhibiting TNF-a secretion and by blunting the
expression of E-selectin. Furthermore, antithrombin-KO
mice developed significantly less metastatic nodules com-
pared to wild-type animals. Altogether, these observations
highlight the relevance of microvasculature ultrastructure
in the process of tumor cell trafficking and migration.
Although its clinical effectiveness has been questioned
when administered to critically ill patients [94], anti-
thrombin therapy may represent a potential option, and
further investigation is needed.
Chemokines are critical mediators involved in the pro-
cess of I/R injury [95–97]. On top of their chemotactic
activity on inflammatory cells, chemokines and their
receptors are involved in cancer cell invasive potential [98–
100]. Man and colleagues demonstrated that CXCL10
(interferon c-induced protein 10) was overexpressed in
small-for-size livers and that upon CXCL10 stimulation,
hepatocellular carcinoma cells displayed pro-migration
morphological changes such as stress fiber and lamellipodia
formation [53]. In addition to these phenotypical changes,
CXCL10 directly impacted on cell motility as assessed in an
in vitro wound healing assay [53] and appeared as pivotal
with regard to endothelial progenitor cell migration [101].
There is a body of evidence supporting the role of
extracellular matrix remodeling in promoting tumor inva-
siveness and metastasis [102]. In particular, matrix
metalloproteinases (MMPs) have been shown to be crucial
mediators of the invasive potential of several cancers,
including colon adenocarcinoma [103] and HCC [104].
Previous research indicates that extracellular matrix
remodeling arising in the setting of I/R injury is mediated
by an increase in MMP-9 expression [105]. Nicoud et al.
demonstrated in a series of elegant experiments that MMP-
9 upregulation after I/R injury promoted the outgrowth of
colorectal carcinoma micrometastases and that doxycy-
cline-mediated MMP inhibition, as well as MMP-9 genetic
silencing, reversed the I/R-related accelerated tumor
growth. Of note, these observations lack confirmatory
evidence from human studies, as Xia et al. [58] did not
report differences in terms of liver tissue mRNA and blood
levels of MMP-2, MMP-9, and E-selectin between patients
undergoing pedicle clamping or not.
Conclusion and Perspective
Although data accumulated from preclinical models uni-
formly point out liver quality as a determinant of cancer
cell implantation and growth, the evidence gathered from
the clinical setting is still limited and ongoing research in
the form of prospective randomized trials should shed light
on this so far unresolved issue. In the meantime, it appears
as reasonable to implement therapeutic approaches to
minimize I/R injury, especially in patients with more
advanced tumor, given their potentially higher pool of
circulating cancer cells. Several therapeutic interventions
such as ischemic pre-conditioning [106], intravenous cor-
ticosteroids [4], prostaglandin E [107], and volatile anes-
thetics [108] have been shown to improve ischemia–
reperfusion, and their specific impact on oncological out-
comes should be assessed. In this regard, we have shown
that graft reperfusion prior to retrieval reduces the HCC
growth in a rat liver transplantation model [55]. Moreover,
neoadjuvant and downstaging strategies appear justified,
provided they do not harmfully delay the access to defin-
itive therapy. Long-term oncological outcomes should be
assessed when comparing various vascular inflow control
procedures and conclusions of RCTs examining early
morbidity, and post-operative hepatocellular damage [109]
may not apply to delayed cancer recurrence. Although
there is better understanding of the interaction between I/R
injury and tumor recurrence, biological mechanisms
underlying these observations remain largely unresolved.
Thus, future research should investigate the cell signaling
pathways involved in cell survival of the injured liver in the
presence of cancer.
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